UY25765A1 - Formulaciones farmacéuticas de liberación controlada - Google Patents

Formulaciones farmacéuticas de liberación controlada

Info

Publication number: UY25765A1
Authority: UY; Uruguay
Prior art keywords: inhibitor; cgmp pde; core; formulations; formulation
Prior art date: 1998-10-23

Application number

UY25765A

Other languages

English (en)

Spanish (es)

Inventor

Ross James Macrae

Elizabeth King

Original Assignee

Pfizer Res And Dev Company Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-10-23

Filing date

1999-10-22

Publication date

2001-08-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269526&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY25765(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-10-23 Priority claimed from GBGB9823192.1A external-priority patent/GB9823192D0/en

1998-11-16 Priority claimed from GBGB9825117.6A external-priority patent/GB9825117D0/en

1998-11-27 Priority claimed from GBGB9826392.4A external-priority patent/GB9826392D0/en

1999-10-22 Application filed by Pfizer Res And Dev Company Nv filed Critical Pfizer Res And Dev Company Nv

2001-08-27 Publication of UY25765A1 publication Critical patent/UY25765A1/es

Links

238000013270 controlled release Methods 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 abstract 7
229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 abstract 7
239000002590 phosphodiesterase V inhibitor Substances 0.000 abstract 7
238000009472 formulation Methods 0.000 abstract 6
239000000203 mixture Substances 0.000 abstract 6
BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 abstract 5
239000011248 coating agent Substances 0.000 abstract 3
238000000576 coating method Methods 0.000 abstract 3
239000012528 membrane Substances 0.000 abstract 3
210000001035 gastrointestinal tract Anatomy 0.000 abstract 2
-1 hydroxypropyl Chemical group 0.000 abstract 2
239000011159 matrix material Substances 0.000 abstract 2
229960003310 sildenafil Drugs 0.000 abstract 2
229920003171 Poly (ethylene oxide) Polymers 0.000 abstract 1
201000001880 Sexual dysfunction Diseases 0.000 abstract 1
239000004480 active ingredient Substances 0.000 abstract 1
229920001577 copolymer Polymers 0.000 abstract 1
238000009792 diffusion process Methods 0.000 abstract 1
230000003628 erosive effect Effects 0.000 abstract 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 1
229960003943 hypromellose Drugs 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000000546 pharmaceutical excipient Substances 0.000 abstract 1
239000004014 plasticizer Substances 0.000 abstract 1
229920000642 polymer Polymers 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
231100000872 sexual dysfunction Toxicity 0.000 abstract 1
238000013268 sustained release Methods 0.000 abstract 1
239000012730 sustained-release form Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Neurosurgery (AREA)
Gynecology & Obstetrics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

UY25765A 1998-10-23 1999-10-22 Formulaciones farmacéuticas de liberación controlada UY25765A1 (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9823192.1A GB9823192D0 (en)	1998-10-23	1998-10-23	Pharmaceutical formulations
GBGB9825117.6A GB9825117D0 (en)	1998-11-16	1998-11-16	Pharmaceutical formulations
GBGB9826392.4A GB9826392D0 (en)	1998-11-27	1998-11-27	Pharmaceutical formulations

Publications (1)

Publication Number	Publication Date
UY25765A1 true UY25765A1 (es)	2001-08-27

Family

ID=27269526

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UY25765A UY25765A1 (es)	1998-10-23	1999-10-22	Formulaciones farmacéuticas de liberación controlada

Country Status (44)

Country	Link
US (1)	US6964780B1 (fr)
EP (1)	EP1123088B1 (fr)
JP (1)	JP2002528408A (fr)
KR (1)	KR20010075659A (fr)
CN (1)	CN1324233A (fr)
AP (1)	AP2001002125A0 (fr)
AT (1)	ATE340562T1 (fr)
AU (1)	AU756509B2 (fr)
BG (1)	BG65323B1 (fr)
BR (1)	BR9914718A (fr)
CA (1)	CA2348086C (fr)
CO (1)	CO5160262A1 (fr)
CR (1)	CR6326A (fr)
CY (1)	CY1106239T1 (fr)
CZ (1)	CZ20011427A3 (fr)
DE (1)	DE69933383T2 (fr)
DK (1)	DK1123088T3 (fr)
DZ (1)	DZ2923A1 (fr)
EA (1)	EA004068B1 (fr)
EE (1)	EE200100235A (fr)
ES (1)	ES2272082T3 (fr)
GT (1)	GT199900184A (fr)
HK (1)	HK1041818A1 (fr)
HR (1)	HRP20010285A2 (fr)
HU (1)	HUP0104318A3 (fr)
ID (1)	ID28232A (fr)
IL (1)	IL141764A (fr)
IS (1)	IS5865A (fr)
MA (1)	MA26700A1 (fr)
MX (1)	MXPA01004011A (fr)
MY (1)	MY130727A (fr)
NO (1)	NO20011933L (fr)
NZ (1)	NZ510275A (fr)
OA (1)	OA11664A (fr)
PA (1)	PA8484301A1 (fr)
PE (1)	PE20001286A1 (fr)
PL (1)	PL195789B1 (fr)
PT (1)	PT1123088E (fr)
SK (1)	SK286473B6 (fr)
TR (1)	TR200101103T2 (fr)
TW (1)	TW577756B (fr)
UA (1)	UA67802C2 (fr)
UY (1)	UY25765A1 (fr)
WO (1)	WO2000024383A1 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TR200001338T2 (tr) *	1997-11-12	2000-08-21	Bayer Aktiengesellschaft	2-Fenil-ikameli imidazotriazinonlar
CA2348871C (fr)	1998-11-02	2009-04-14	John G. Devane	Composition a liberation modifiee multiparticulaire
ATE526950T1 (de)	1999-10-29	2011-10-15	Euro Celtique Sa	Hydrocodon-formulierungen mit gesteuerter freisetzung
US10179130B2 (en)	1999-10-29	2019-01-15	Purdue Pharma L.P.	Controlled release hydrocodone formulations
ATE552013T1 (de)	2000-09-06	2012-04-15	Mitsubishi Tanabe Pharma Corp	Zubereitungen zur oralen anwendung
EP2283829A1 (fr)	2000-10-30	2011-02-16	Euro-Celtique S.A.	Formulations d'hydrocodone à liberation lente
EP1366760B1 (fr) *	2001-02-15	2010-06-30	Mitsubishi Tanabe Pharma Corporation	Comprimes a dissolution rapide dans la cavite buccale
US10675280B2 (en)	2001-10-20	2020-06-09	Sprout Pharmaceuticals, Inc.	Treating sexual desire disorders with flibanserin
UA78974C2 (en)	2001-10-20	2007-05-10	Boehringer Ingelheim Pharma	Use of flibanserin for treating disorders of sexual desire
ITMI20020515A1 (it) *	2002-03-12	2003-09-12	Jagotec Ag	Sistema per il rilasco controllato di uno o piu' principi attivi
GB0318824D0 (en) *	2003-08-11	2003-09-10	Glaxo Group Ltd	Novel composition
NZ551356A (en)	2004-05-11	2009-09-25	Emotional Brain Bv	Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
DE102004023069A1 (de) *	2004-05-11	2005-12-08	Bayer Healthcare Ag	Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
GB0421121D0 (en) *	2004-09-22	2004-10-27	Natrocell Technologies Ltd	Composite rodenticide
DE102005001989A1 (de) *	2005-01-15	2006-07-20	Bayer Healthcare Ag	Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009241A1 (de) *	2005-03-01	2006-09-07	Bayer Healthcare Ag	Arzneiformen mit kontrollierter Bioverfügbarkeit
DE102005009240A1 (de)	2005-03-01	2006-09-07	Bayer Healthcare Ag	Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
WO2007000764A2 (fr) *	2005-06-27	2007-01-04	Daniel Drai	Compositions et methodes permettant d'ameliorer la fonction sexuelle
ES2646326T3 (es)	2005-08-03	2017-12-13	Sprout Pharmaceuticals, Inc.	Uso de flibanserina en el tratamiento de la obesidad
CA2623657A1 (fr) *	2005-09-29	2007-04-12	Bayer Healthcare Ag	Inhibiteurs pde et combinaisons de ceux-ci pour traiter des troubles urinaires
WO2007048803A1 (fr)	2005-10-29	2007-05-03	Boehringer Ingelheim International Gmbh	Derives de benzimidazolone utiles pour le traitement des troubles premenstruels et d'autres troubles sexuels chez la femme
EP1790343A1 (fr) *	2005-11-11	2007-05-30	Emotional Brain B.V.	Compositions pharmaceutiques et leur utilisation pour le traitement des dysfonctions sexuelles chez la femme
WO2008000760A1 (fr)	2006-06-30	2008-01-03	Boehringer Ingelheim International Gmbh	Flibansérine dans le traitement de l'incontinence urinaire et des maladies associées
BRPI0716439B8 (pt)	2006-08-14	2021-05-25	Boehringer Ingelheim Int	sistemas de liberação farmacêutico compreendendo flibanserina, processo para preparação e uso dos mesmos
BRPI0716436B8 (pt)	2006-08-25	2021-05-25	Boehringer Ingelheim Int	sistema de liberação controlada e método para fabricação do mesmo
EP1925307A1 (fr) *	2006-11-03	2008-05-28	Emotional Brain B.V.	Utilisation de 3-alpha-androstanediol pour le traitement des dysfonctions sexuelles
US20080226715A1 (en) *	2007-03-16	2008-09-18	Albert Cha	Therapeutic compositions and methods
EP2167057A1 (fr) *	2007-06-13	2010-03-31	Bayer HealthCare AG	Inhibiteurs de la phosphodiestérase (pde) destinés au traitement des troubles de l'audition
CL2008002693A1 (es)	2007-09-12	2009-10-16	Boehringer Ingelheim Int	Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
US20110033506A1 (en) *	2008-02-08	2011-02-10	Adel Penhasi	Combination dosage form of low-dose modafinil and low-dose sildenafil
EP2374460A4 (fr) *	2008-12-12	2013-08-21	Rhein Siegfried Sa De Cv	Composition de sildénafil à libération pulsée et son procédé de préparation
KR101004205B1 (ko) *	2008-12-17	2010-12-24	동아제약주식회사	유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
EA015250B9 (ru) *	2010-11-19	2013-10-30	Тева Фармасьютикал Индастриз, Лтд.	Таблетка силденафила, обеспечивающая модифицированную фармакокинетику, и способ ее изготовления
PH12013502325A1 (en)	2011-05-13	2014-02-10	Eb Ip Hybritabs B V	Drug delivery system
WO2013016144A1 (fr) *	2011-07-22	2013-01-31	Pom Wonderful, Llc	Compositions comprenant des polyphénols de grenade en combinaison avec des composés de traitement de la dysérection, et procédé de traitement de la dysérection à l'aide de celle-ci
WO2017168174A1 (fr) *	2016-04-02	2017-10-05	N4 Pharma Uk Limited	Nouvelles formes pharmaceutiques du sildénafil
CN113995727B (zh) *	2021-11-08	2023-04-07	山东鲁抗医药股份有限公司	一种5型磷酸二酯酶抑制剂片剂及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3952741A (en)	1975-01-09	1976-04-27	Bend Research Inc.	Controlled release delivery system by an osmotic bursting mechanism
JPS54119021A (en) *	1978-03-06	1979-09-14	Nippon Kayaku Co Ltd	Carcinostatic agent
CH648754A5 (en) *	1979-08-16	1985-04-15	Ciba Geigy Ag	Pharmaceutical slow release tablet
JPS5748908A (en) *	1980-09-08	1982-03-20	Kyorin Pharmaceut Co Ltd	Prolonged release type nicomol pharmaceutical
FR2624732B1 (fr)	1987-12-21	1991-02-15	Synthelabo	Formulation pharmaceutique a liberation prolongee
MC2025A1 (fr) *	1988-04-20	1990-04-25	Asta Pharma Ag	Medicament contenant de l'azelastine et capable de liberer celle-ci de facon controlee
IT1229856B (it) *	1989-04-20	1991-09-13	Recordati Chem Pharm	Compresse a rilascio controllato contenenti flavossato.
US5474784A (en)	1990-03-02	1995-12-12	British Technology Group Limited	Dispensing device
GB9013750D0 (en)	1990-06-20	1990-08-08	Pfizer Ltd	Therapeutic agents
GB9114760D0 (en)	1991-07-09	1991-08-28	Pfizer Ltd	Therapeutic agents
PT621032E (pt) *	1993-04-23	2001-01-31	Novartis Ag	Dispositivo de distribuicao de libertacao controlada de farmaco
GB9301192D0 (en) *	1993-06-09	1993-06-09	Trott Francis W	Flower shaped mechanised table
US5464633A (en)	1994-05-24	1995-11-07	Jagotec Ag	Pharmaceutical tablets releasing the active substance after a definite period of time
US5656629A (en) *	1995-03-10	1997-08-12	Sanofi Winthrop, Inc.	6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
US5888534A (en)	1995-06-13	1999-03-30	Pentech Pharmaceuticals, Inc.	Controlled release of drugs delivered by sublingual or buccal administration
GB9514464D0 (en) *	1995-07-14	1995-09-13	Glaxo Lab Sa	Medicaments
GB9523752D0 (en) *	1995-11-21	1996-01-24	Pfizer Ltd	Pharmaceutical formulations
JPH1067657A (ja) *	1996-06-18	1998-03-10	Otsuka Pharmaceut Co Ltd	マルチプルユニット型持続性製剤
WO1997048382A2 (fr) *	1996-06-18	1997-12-24	Otsuka Pharmaceutical Co., Ltd.	Preparation medicamenteuse d'action prolongee, de type a plusieurs unites
HUP0002744A3 (en) *	1997-01-06	2001-01-29	Pfizer	Rapidly releasing and taste-masking pharmaceutical dosage form
US6046177A (en) *	1997-05-05	2000-04-04	Cydex, Inc.	Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US5874418A (en) *	1997-05-05	1999-02-23	Cydex, Inc.	Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6403597B1 (en) *	1997-10-28	2002-06-11	Vivus, Inc.	Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6277884B1 (en) *	1998-06-01	2001-08-21	Nitromed, Inc.	Treatment of sexual dysfunction with N-hydroxyguanidine compounds
DK1109814T3 (da) *	1998-09-04	2004-08-02	Ortho Mcneil Pharm Inc	5-Heterocyclylpyrazolo[4,3-d]pyrimidin-7-oner til behandling af mandlig erektil dysfunktion

1999
- 1999-04-10 UA UA2001042718A patent/UA67802C2/uk unknown
- 1999-10-01 TW TW088116973A patent/TW577756B/zh not_active IP Right Cessation
- 1999-10-04 AT AT99946377T patent/ATE340562T1/de not_active IP Right Cessation
- 1999-10-04 AU AU58787/99A patent/AU756509B2/en not_active Ceased
- 1999-10-04 CA CA002348086A patent/CA2348086C/fr not_active Expired - Fee Related
- 1999-10-04 IL IL141764A patent/IL141764A/en unknown
- 1999-10-04 PL PL99347476A patent/PL195789B1/pl not_active IP Right Cessation
- 1999-10-04 EA EA200100298A patent/EA004068B1/ru not_active IP Right Cessation
- 1999-10-04 HU HU0104318A patent/HUP0104318A3/hu unknown
- 1999-10-04 DK DK99946377T patent/DK1123088T3/da active
- 1999-10-04 TR TR2001/01103T patent/TR200101103T2/xx unknown
- 1999-10-04 BR BR9914718-1A patent/BR9914718A/pt not_active Application Discontinuation
- 1999-10-04 HK HK02103588.0A patent/HK1041818A1/zh unknown
- 1999-10-04 CZ CZ20011427A patent/CZ20011427A3/cs unknown
- 1999-10-04 SK SK519-2001A patent/SK286473B6/sk unknown
- 1999-10-04 EP EP99946377A patent/EP1123088B1/fr not_active Expired - Lifetime
- 1999-10-04 CN CN99812510A patent/CN1324233A/zh active Pending
- 1999-10-04 AP APAP/P/2001/002125A patent/AP2001002125A0/en unknown
- 1999-10-04 JP JP2000577993A patent/JP2002528408A/ja active Pending
- 1999-10-04 KR KR1020017005042A patent/KR20010075659A/ko not_active Ceased
- 1999-10-04 HR HR20010285A patent/HRP20010285A2/xx not_active Application Discontinuation
- 1999-10-04 OA OA1200100093A patent/OA11664A/en unknown
- 1999-10-04 NZ NZ510275A patent/NZ510275A/en unknown
- 1999-10-04 MX MXPA01004011A patent/MXPA01004011A/es active IP Right Grant
- 1999-10-04 ES ES99946377T patent/ES2272082T3/es not_active Expired - Lifetime
- 1999-10-04 EE EEP200100235A patent/EE200100235A/xx unknown
- 1999-10-04 WO PCT/IB1999/001619 patent/WO2000024383A1/fr not_active Ceased
- 1999-10-04 DE DE69933383T patent/DE69933383T2/de not_active Expired - Fee Related
- 1999-10-04 ID IDW20010891A patent/ID28232A/id unknown
- 1999-10-04 PT PT99946377T patent/PT1123088E/pt unknown
- 1999-10-18 PA PA19998484301A patent/PA8484301A1/es unknown
- 1999-10-20 DZ DZ990223A patent/DZ2923A1/fr active
- 1999-10-20 MA MA25820A patent/MA26700A1/fr unknown
- 1999-10-20 MY MYPI99004535A patent/MY130727A/en unknown
- 1999-10-21 PE PE1999001062A patent/PE20001286A1/es not_active Application Discontinuation
- 1999-10-22 CO CO99066970A patent/CO5160262A1/es unknown
- 1999-10-22 GT GT199900184A patent/GT199900184A/es unknown
- 1999-10-22 US US09/425,622 patent/US6964780B1/en not_active Expired - Fee Related
- 1999-10-22 UY UY25765A patent/UY25765A1/es not_active Application Discontinuation
2001
- 2001-02-27 IS IS5865A patent/IS5865A/is unknown
- 2001-03-14 CR CR6326A patent/CR6326A/es not_active Application Discontinuation
- 2001-04-19 NO NO20011933A patent/NO20011933L/no not_active Application Discontinuation
- 2001-04-24 BG BG105465A patent/BG65323B1/bg unknown
2006
- 2006-11-13 CY CY20061101644T patent/CY1106239T1/el unknown

Also Published As

Publication number	Publication date
OA11664A (en)	2005-01-07
MXPA01004011A (es)	2003-03-10
IL141764A0 (en)	2002-03-10
HK1041818A1 (zh)	2002-07-26
CZ20011427A3 (cs)	2001-10-17
GT199900184A (es)	2001-04-14
DE69933383D1 (de)	2006-11-09
NO20011933L (no)	2001-06-25
TR200101103T2 (tr)	2001-09-21
CA2348086C (fr)	2007-01-23
EE200100235A (et)	2002-08-15
EA004068B1 (ru)	2003-12-25
CN1324233A (zh)	2001-11-28
EP1123088A1 (fr)	2001-08-16
CY1106239T1 (el)	2011-06-08
IS5865A (is)	2001-02-27
CR6326A (es)	2004-02-23
MA26700A1 (fr)	2004-12-20
SK5192001A3 (en)	2002-09-10
ES2272082T3 (es)	2007-04-16
CA2348086A1 (fr)	2000-05-04
ATE340562T1 (de)	2006-10-15
AU5878799A (en)	2000-05-15
EP1123088B1 (fr)	2006-09-27
PE20001286A1 (es)	2000-11-22
NO20011933D0 (no)	2001-04-19
US6964780B1 (en)	2005-11-15
HRP20010285A2 (en)	2002-06-30
EA200100298A1 (ru)	2001-08-27
KR20010075659A (ko)	2001-08-09
ID28232A (id)	2001-05-10
HUP0104318A2 (hu)	2002-03-28
MY130727A (en)	2007-07-31
HUP0104318A3 (en)	2003-12-29
TW577756B (en)	2004-03-01
BR9914718A (pt)	2001-07-10
PL347476A1 (en)	2002-04-08
NZ510275A (en)	2003-07-25
BG105465A (bg)	2001-12-29
BG65323B1 (bg)	2008-02-29
DZ2923A1 (fr)	2004-03-01
UA67802C2 (uk)	2004-07-15
AU756509B2 (en)	2003-01-16
SK286473B6 (sk)	2008-11-06
IL141764A (en)	2008-06-05
JP2002528408A (ja)	2002-09-03
DK1123088T3 (da)	2007-01-02
DE69933383T2 (de)	2007-02-01
WO2000024383A1 (fr)	2000-05-04
PT1123088E (pt)	2007-01-31
CO5160262A1 (es)	2002-05-30
PA8484301A1 (es)	2000-09-29
PL195789B1 (pl)	2007-10-31
AP2001002125A0 (en)	2001-04-04

Legal Events

Date	Code	Title	Description
2011-06-23	109	Application deemed to be withdrawn	Effective date: 20110623

Publication	Publication Date	Title
ES2593582T3 (es)	2016-12-09	Formulación de comprimido recubierto y método
US7611728B2 (en)	2009-11-03	Osmotic delivery of therapeutic compounds by solubility enhancement
ES2769357T3 (es)	2020-06-25	Formas farmacéuticas de apixaban
ES2585731T3 (es)	2016-10-07	Forma de dosificación farmacéutica que comprende nifedipino o nisoldipino y un antagonista de angiotensina II y/o un diurético
ES2292819T3 (es)	2008-03-16	Composiciones farmaceuticas que comprenden acido micofenolico o sal de micofenolato.
CA2566278A1 (fr)	2005-11-24	Formulations a liberation controlee contenant du vardenafil
UA67802C2 (uk)	2004-07-15	Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
CZ20002314A3 (cs)	2000-11-15	Orální farmaceutická dávková forma s prodlouženým uvolňováním
JP2004534057A5 (fr)	2005-12-22
CN103096881A (zh)	2013-05-08	含有具有不愉快味道的药物的膜制剂
WO2004108162A3 (fr)	2005-03-10	Composition pharmaceutique et methode de traitement
ES2435943T3 (es)	2013-12-26	Formulaciones de vildagliptina
RU2007111755A (ru)	2008-11-20	Фармацевтические полидисперсные композиции, включающие микофенольную кислоту или микофенолят натрия, и комбинации композиций с рапамицином
KR102051132B1 (ko)	2019-12-02	미라베그론 또는 이의 염을 포함하는 방출조절용 약제학적 조성물
ES2561085T3 (es)	2016-02-24	Preparación de liberación lenta de aceclofenaco que proporciona un efecto clínico farmacológico óptimo cuando se administra una vez al día
ITMI952221A1 (it)	1997-04-27	Composizioni farmaceutiche solide per uso vaginale
HK1219889A1 (zh)	2017-04-21	包含他达拉非和坦洛新的药物胶囊复合制剂
US20150224060A1 (en)	2015-08-13	Gastric retentive tablet compositions
ES2689919T3 (es)	2018-11-16	Formulación farmacéutica multicapa
JPWO2003043661A1 (ja)	2005-03-10	酸に不安定な生理活性化合物を含有する製剤組成物及びその製法
RU2008103551A (ru)	2009-08-20	Фармацевтические препаративные формы, содержащие комбинацию действующих веществ из нифедипина и/или низолдипина и антагониста ангиотензина-ii
HRP20080252T3 (hr)	2008-07-31	Oralni antimikrobni farmaceutski pripravci
WO2010023690A2 (fr)	2010-03-04	Formulation à libération prolongée d'amisulpride
HRP980074A2 (en)	1998-10-31	Pharmaceutical formulations in dry form for the oral administration of a cyclic quaternary ammonium compound
AU2016231883A1 (en)	2017-10-26	Pharmaceutical compositions of dimethyl fumarate